Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Ascension Health
483
•Ascension Health•November 9, 2017

Ascension Health – FDA 483, Nov 9, 2017

Record Details

An FDA inspection of Wheaton Franciscan Healthcare IRB #1, an Institutional Review Board, was conducted from November 2 to November 9, 2017. The inspection identified two significant observations related to the management and documentation of IRB membership and meeting minutes, indicating a need for improved compliance with regulatory standards.

The primary issue noted was the failure to maintain an accurate and updated roster of IRB members. Specifically, the prepared list of members, which should detail names, degrees, representative capacity, and experience, did not consistently reflect the actual individuals attending and voting at various IRB meetings throughout 2016 and 2017. This discrepancy was observed in multiple meeting minutes, suggesting a systemic lack of timely updates to membership records.

Secondly, the inspection found that minutes of IRB meetings were not sufficiently detailed, particularly concerning attendance and voting records. There were documented inaccuracies in the minutes for several meetings in 2016 and 2017 regarding which members were present, appointed, or participated in voting. This indicates a deficiency in maintaining clear and precise records of IRB proceedings.

These observations, issued under a Form FDA 483, highlight concerns regarding the integrity of the IRB's operational documentation, which is crucial for ensuring the proper oversight of human subject research. While the FDA 483 document does not explicitly list "required actions," Wheaton Franciscan Healthcare is expected to address these observations by implementing appropriate corrective actions to bring its practices into full compliance with relevant FDA regulations. The firm has the opportunity to discuss its objections or planned corrective actions with the FDA.

Company
Ascension Health
Inspection date
November 9, 2017
Product type
Drugs
Office
Minneapolis District Office
People
  • Denise L. Burosh (Bioresearch Monitoring Specialis)
  • Jackie L. Blundon (Director)
View Company Profile

ID · c74a29a8-6216-44f8-bdc4-8170279c4153

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ascension Health
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.